-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abiraterone Acetate in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abiraterone Acetate in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abiraterone Acetate in Hormone-Sensitive Prostate Cancer Drug Details: Abiraterone acetate...
-
Product Insights
NewHormone-Sensitive Prostate Cancer – Drugs In Development, 2024
Empower your strategies with our Hormone-Sensitive Prostate Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Hormone-sensitive prostate cancer (HSPC) is a type of prostate cancer that responds to hormone therapy, which aims to reduce or block the production or action of androgens such as testosterone. Androgens are male sex hormones that stimulate the growth of normal and cancerous prostate cells. Most prostate cancers are initially hormone-sensitive, but they may become castration-resistant over time, meaning that they...
-
Product Insights
NewCystic Fibrosis – Drugs In Development, 2024
Empower your strategies with our Cystic Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose, and severe constipation. Risk factors include family history and race (Northern...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-520 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NUV-520 in Non-Small Cell Lung Cancer Drug Details: NUV-520 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:Abiraterone acetate (DRGT-45) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Refractory Acute Myeloid Leukemia Drug Details: Iomab-B, a radioimmunoconjugate (BC8-I-131...
-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – amlodipine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry amlodipine Drug Details Amlodipine (DRGT-119) is under development for the treatment of chronic anal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – abiraterone acetate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry abiraterone acetate Drug Details Abiraterone acetate (DRGT-45) is under development for the treatment of...